Home / Episodes / Wed, Nov 18, 2026

SELLAS' AML Survival Win Sets Up Its FDA Push & Isomorphic Raises $5B

Wed, Nov 18, 2026 15 min Hosts: Alex Mercer & Maya Patel
▶ Listen

SELLAS reports median survival of 24.0 months with its vaccine versus 14.7 with investigator-chosen care in REGAL, a Phase 3 trial in later-remission AML; we unpack the filing stakes and topline limits. Isomorphic Labs raises $5 billion to move AI drug discovery toward human trials. We examine GSK's Nuvalent-derived Nelkarmi (neladalkib) approval for previously treated ALK-positive lung cancer and new details in the existing FDA rejection letter for Summit's ivonescimab. The roundup covers Beren's Lembaz (adrabetadex) in infantile-onset Niemann-Pick type C, Novartis' Cosentyx (secukinumab) in polymyalgia rheumatica, and Helus' investigational HLP003 depression results—with evidence limits and safety tradeoffs.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

Close out your day

The whole read, every morning

The daily Closeout in under 15 minutes — trial readouts, FDA decisions, and the deal math behind them. Free.

Subscribe →